{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T12:32:46Z","timestamp":1770985966226,"version":"3.50.1"},"reference-count":12,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2018,6,1]],"date-time":"2018-06-01T00:00:00Z","timestamp":1527811200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,6,1]],"date-time":"2018-06-01T00:00:00Z","timestamp":1527811200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinical-genitourinary-cancer.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Genitourinary Cancer"],"published-print":{"date-parts":[[2018,6]]},"DOI":"10.1016\/j.clgc.2017.12.014","type":"journal-article","created":{"date-parts":[[2018,1,4]],"date-time":"2018-01-04T03:34:25Z","timestamp":1515036865000},"page":"e663-e667","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"title":["Drug Holiday in Metastatic Renal-Cell Carcinoma Patients Treated With Vascular Endothelial Growth Factor Receptor Inhibitors"],"prefix":"10.1016","volume":"16","author":[{"given":"Kriti","family":"Mittal","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0527-2964","authenticated-orcid":false,"given":"Lisa","family":"Derosa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laurence","family":"Albiges","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura","family":"Wood","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul","family":"Elson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Timothy","family":"Gilligan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jorge","family":"Garcia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert","family":"Dreicer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bernard","family":"Escudier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brian","family":"Rini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clgc.2017.12.014_bib1","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1200\/JCO.2011.36.4133","article-title":"Randomized phase II trial of sunitinib on an intermittent versus continuous dosing schedule as first-line therapy for advanced renal cell carcinoma","volume":"30","author":"Motzer","year":"2012","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clgc.2017.12.014_bib2","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1016\/j.ejca.2014.01.025","article-title":"A\u00a02 weeks on and 1 week off schedule of sunitinib is associated with decreased toxicity in metastatic renal cell carcinoma","volume":"50","author":"Najjar","year":"2014","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.clgc.2017.12.014_bib3","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1186\/1479-5876-9-220","article-title":"High dose intermittent sorafenib shows improved efficacy over conventional continuous dose in renal cell carcinoma","volume":"9","author":"Wang","year":"2011","journal-title":"J\u00a0Transl Med"},{"key":"10.1016\/j.clgc.2017.12.014_bib4","doi-asserted-by":"crossref","first-page":"1764","DOI":"10.1200\/JCO.2016.71.1184","article-title":"A phase II study of intermittent sunitinib in previously untreated patients with metastatic renal cell carcinoma","volume":"35","author":"Ornstein","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clgc.2017.12.014_bib5","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1016\/j.eururo.2008.10.021","article-title":"Can tyrosine kinase inhibitors be discontinued in patients with metastatic renal cell carcinoma and a complete response to treatment? A multicentre, retrospective analysis","volume":"55","author":"Johannsen","year":"2009","journal-title":"Eur Urol"},{"key":"10.1016\/j.clgc.2017.12.014_bib6","first-page":"1494","article-title":"Discontinuation of the tyrosine kinase inhibitor sunitinib in patients with metastatic renal cell carcinoma: a case series","volume":"11","author":"Neuhaus","year":"2014","journal-title":"Urol J"},{"key":"10.1016\/j.clgc.2017.12.014_bib7","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1200\/JCO.2011.37.2516","article-title":"Complete remission with tyrosine kinase inhibitors in renal cell carcinoma","volume":"30","author":"Albiges","year":"2012","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clgc.2017.12.014_bib8","doi-asserted-by":"crossref","first-page":"3277","DOI":"10.1002\/cncr.26666","article-title":"Cessation of vascular endothelial growth factor\u2013targeted therapy in patients with metastatic renal cell carcinoma: feasibility and clinical outcome","volume":"118","author":"Sadeghi","year":"2012","journal-title":"Cancer"},{"key":"10.1016\/j.clgc.2017.12.014_bib9","doi-asserted-by":"crossref","first-page":"2999","DOI":"10.1002\/cncr.28151","article-title":"Metastatic non-clear cell renal cell carcinoma treated with targeted therapy agents: characterization of survival outcome and application of the international mRCC Database Consortium criteria","volume":"119","author":"Kroeger","year":"2013","journal-title":"Cancer"},{"key":"10.1016\/j.clgc.2017.12.014_bib10","doi-asserted-by":"crossref","first-page":"5","DOI":"10.3892\/ijo.2013.2181","article-title":"Angiogenesis inhibitor therapies for advanced renal cell carcinoma: toxicity and treatment patterns in clinical practice from a global medical chart review","volume":"44","author":"Oh","year":"2014","journal-title":"Int J Oncol"},{"key":"10.1016\/j.clgc.2017.12.014_bib11","doi-asserted-by":"crossref","first-page":"2098","DOI":"10.1093\/annonc\/mdt130","article-title":"A\u00a0prospective evaluation of VEGF-targeted treatment cessation in metastatic clear cell renal cancer","volume":"24","author":"Powles","year":"2013","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clgc.2017.12.014_bib12","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1186\/1471-2407-12-598","volume":"12","author":"Collinson","year":"2012","journal-title":"BMC Cancer"}],"container-title":["Clinical Genitourinary Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1558767318300028?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1558767318300028?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T11:30:15Z","timestamp":1761564615000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1558767318300028"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,6]]},"references-count":12,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2018,6]]}},"alternative-id":["S1558767318300028"],"URL":"https:\/\/doi.org\/10.1016\/j.clgc.2017.12.014","relation":{},"ISSN":["1558-7673"],"issn-type":[{"value":"1558-7673","type":"print"}],"subject":[],"published":{"date-parts":[[2018,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Drug Holiday in Metastatic Renal-Cell Carcinoma Patients Treated With Vascular Endothelial Growth Factor Receptor Inhibitors","name":"articletitle","label":"Article Title"},{"value":"Clinical Genitourinary Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clgc.2017.12.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}